Navigation Links
Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting
Date:4/29/2013

ROCKVILLE, Md., April 29, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that final data on the intraspinal delivery method employed in its NSI-566 Phase I trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig 's disease) was presented today at the American Association of Neurological Surgeons Annual Meeting. In a presentation called "Intraspinal Stem Cell Transplantation in ALS, A Phase I Trial: Cervical Microinjection Safety Outcomes," Jonathan Patrick Riley , MD, of the Department of Neurological Surgery at Emory University, in Atlanta, GA, presented data from all 18 procedures, in 15 patients, treated in Phase I. (Three of the patients returned to the trial for subsequent treatments in a different region of the spinal cord.) The study found that none of the patients experienced neurological worsening from injections into either the upper (cervical) or lower (lumbar) region of the back, nor was there any evidence of spinal cord injury. The cells also appeared to be safe with no evidence of toxicity. Researchers further noted that, even in the vulnerable ALS spinal cord, serial injections were well-tolerated. They concluded that the approach of starting in the lower region of the spine, where the potential risk to the patient was less, and then progressing upwards, might not be required in future trials, and that this intraspinal delivery technique is an option for treating other neurodegenerative and traumatic spinal cord disorders.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"This is an extremely important confirmation of the safety and tolerability of both the route of administration and our cells," said Karl Johe , PhD, Neuralstem Chairman and Chief Scientific Officer and a study author. "These patients are in many ways more fragile, and at greater risk from spinal surgery, than patients with other types of diseases or injuries where our cell therapy may be applicable. That our cells and method of delivery are safe in ALS patients bodes very well for expanding to other indications. We expect to commence our FDA-approved Phase I trial in chronic spinal cord injury later this year using the same methodology. We want to thank the surgeons at Emory, who developed these techniques, as well as the patients and their families who have taken part in the trial."

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, in February 2013, and has received FDA approval to begin Phase II. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in the last cohort of a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn

Cautionary Statement Regarding Forward Looking Information                                                    

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2012.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
2. Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention
3. Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis
4. Neuralstem Secures $8 Million In Debt Financing From Hercules
5. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
6. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
7. Neuralstem to Raise $7.0 Million in Registered Direct Offering
8. Neuralstem Announces Proposed Public Offering
9. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
10. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
11. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
(Date:8/4/2017)... -- The search for test results that can be ... long been the goal of healthcare providers and the ... largest meeting of lab professionals and IVD firms this ... Kalorama Information.  The firm said scores of companies with ... and software were at the American Association for Clinical ...
(Date:8/2/2017)... 2, 2017  Life Flight Network and PeaceHealth Oregon Network ... patient care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, ... and Life Flight Network work collaboratively to move patients who ... when a time sensitive emergency exists. ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that provides ... employers connect with physicians and advanced practitioners like nurse practitioners and ... in August through November of this year. The online career fairs will allow job ...
(Date:8/21/2017)... ... August 22, 2017 , ... The National Association ... 2017-2018 inductee into its VIP Woman of the Year Circle. She is recognized ... networking organization exclusively for professional women, boasting more than 850,000 members, a thriving ...
(Date:8/21/2017)... ... August 21, 2017 , ... FCPX LUT Monochromatic Volume 2 ... quickly and easily add washed color grades to footage. A LUT is a Lookup ... pixel’s color to the corresponding color indicated by the table. This pack comes with ...
(Date:8/21/2017)... Beach, California (PRWEB) , ... August 21, 2017 , ... ... raise money and awareness for Alzheimer’s Family Center. , Guests will be able ... from Newport Beach Plaza, Braised Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce ...
(Date:8/21/2017)... ... August 21, 2017 , ... Duncan Insurance ... serving the people of Michigan. The new initiative fundraises for the Kalamazoo Humane ... very forefront of animal protection and welfare by addressing the root causes of ...
Breaking Medicine News(10 mins):